Corona Remedies
MainboardGMP is market estimated & subject to change. Not a guaranteed listing price.
Corona Remedies IPO Issue Details
| Issue Price | ₹1008-1062 per equity share |
| Face Value | ₹10 Per Equity Share |
| Total Issue Size | 61,71,101 shares(aggregating up to ₹655.37 crore) |
| Fresh Share | N/A |
| Offer For Sale | N/A |
| Listing at | BSE, NSE |
| List Price | Listing Price: 1470.0 (Mainboard) |
| Listing Date | 2025-12-15 |
| Lead Manager | JM Financial LtdIIFL Capital Services LtdKotak Mahindra Capital Co.LtdKotak Mahindra Capital Co.Ltd. |
| Registrar | Bigshare Services Pvt Ltd |
Corona Remedies IPO Live Subscription
Last Updated: 10 Dec, 13:42Total Subscription
144.49 x
Based on live data from BSE/NSE
Corona Remedies IPO Subscription Analysis And Details
| Day / Date | QIB | NII (HNI) bNII (>10L) sNII (<10L) | Retail | Total |
|---|---|---|---|---|
| Shares Offered reserved quota | 12,21,729 | 9,16,960 6,11,307 3,05,653 | 21,39,573 | 43,36,298 |
Day 18 Dec 2025 | 0.00 xx | 0.84 0.53 1.45 | 0.93 xx | 0.66 xx |
Day 29 Dec 2025 | 1.76 xx | 28.32 29.02 26.92 | 6.81 xx | 9.90 xx |
Day 310 Dec 2025 | 293.80 xx | 220.18 246.67 167.20 | 30.29 xx | 144.49 xx |
Total Applications
42,38,858
Retail Subscription
Profit Estimator
Calculate your potential listing gains
Investment Amount
₹14,490.00
Current GMP
+₹211.08
Estimated Profit
Corona Remedies IPO Financial Scorecard
Corona Remedies IPO Peer Comparison
| Company Name | Revenue | RoNW | PE Ratio |
|---|---|---|---|
| Corona Remedies | 1196 | 24.6% | N/A |
| Abbott India | 6409 | 33.4% | 45.1 |
| Alkem Lab | 12964 | 18.0% | 31.3 |
| Eris Life | 2893 | 12.2% | 61.8 |
| Glaxosmithkline | 3749 | 47.5% | 46.8 |
| J B Chemicals | 3917 | 19.2% | 42.6 |
| Mankind | 12207 | 13.8% | 45.7 |
| Pfizer | 2281 | 18.2% | 29.6 |
| Sanofi | 2013 | 48.0% | 24.4 |
| Torrent | 11516 | 25.1% | 65.9 |
Corona Remedies IPO Financial Results
| Metric | 30-Jun-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|---|---|---|---|
| Assets | 1012.38 | 929.86 | 830.58 | 595.02 |
| Revenue | 348.56 | 1202.35 | 1020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| Net Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves & Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
* In Cr.
IPO Timeline
IPO Open
8 Dec 2025
IPO Close
10 Dec 2025
Allotment
11 Dec 2025
Refunds
12 Dec 2025
Demat Credit
13 Dec 2025
Listing
15 Dec 2025
IPO Open
8 Dec 2025
IPO Close
10 Dec 2025
Allotment
11 Dec 2025
Refunds
12 Dec 2025
Demat Credit
13 Dec 2025
Listing
15 Dec 2025
Corona Remedies IPO Lot Size & Application
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO About Company
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.
The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
Presently, the company owns two manufacturing facilities located in the states of Gujarat.
As of December 31, 2024, the company had 88 R&D employees.
Corona Remedies IPO Share Holding
Pre Issue
72.50%
Post Issue
N/A%
Promoters
COMPANY
Corona Remedies
CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059
PHONE
+91 79 4023 3000
REGISTRAR
Bigshare Services Pvt Ltd
Common Questions
To decide on investing in Corona Remedies, consider its financial health. The company reported a revenue of {"30-Jun-25": "348.56", "31-Mar-25": "1202.35", "31-Mar-24": "1020.93", "31-Mar-23": "891.10"} and a profit after tax of {"30-Jun-25": "46.20", "31-Mar-25": "149.43", "31-Mar-24": "90.50", "31-Mar-23": "84.93"}. It has a P/E ratio of 43.47 and a RoNW of 24.65%%. Always review the RHP and consult a financial advisor before investing.
Based on the latest Grey Market Premium (GMP) of ₹0, the expected listing price is around ₹1062 per share. This suggests a potential listing gain of approx 38.42%%. (Note: GMP is volatile and not a guarantee).
The IPO opens for subscription on 8 Dec, 2025 and closes on 10 Dec, 2025. The allotment status will be finalized by 11 Dec, 2025, and listing is expected on 15 Dec, 2025.
Retail investors need to apply for a minimum of 1 lot (14 shares) which requires an investment of ₹14,868. For HNI investors, the minimum investment is 14 lots (196 shares) amounting to ₹2,08,152.
You can check the allotment status on the registrar's website (Bigshare Services Pvt Ltd) or via the BSE/NSE website once the allotment is finalized on 11 Dec, 2025.
The price band for Corona Remedies IPO is set at ₹1008 to ₹1062 per share.
The minimum market lot (lot size) for Corona Remedies IPO is 14 shares. Retail investors can apply for up to 13 lots (182 shares or ₹1,93,284).
The issue is divided into categories: Qualified Institutional Buyers (QIB) get N/A%, Non-Institutional Investors (NII/HNI) get N/A%, and Retail investors are allocated N/A% of the shares.